Answer
Safety and effectiveness have not been established in children and adolescents aged 6 to 18 years, and there is no relevant licensed use below age 6 for migraine prevention.
Sources for this answer
- Vyepti 100 mg concentrate for solution for infusion (300 mg not marketed)emc · SmPC Current selected SmPC · Version 4